Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261957 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 477
- Enrollment target
NCT06261957: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT06261957 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 477 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06261957, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 477 participants
- Enrollment target
Study Summary
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Interventions
- DRUG Salbutamol HFA-134a
- DRUG Salbutamol HFA-152a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 3 |
What the finished NCT06261957 record still lists
NCT06261957 is an interventional study that assigns participants to a tested intervention. The registered 477 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which Salbutamol HFA-134a is the first listed.
NCT06261957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06261957 about?
NCT06261957 is a clinical study titled "A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma". The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
What is the current status of trial NCT06261957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 477 participants. The study started on 2024-05-31. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT06261957?
The interventions under investigation include: Salbutamol HFA-134a (DRUG), Salbutamol HFA-152a (DRUG).
Who is sponsoring clinical trial NCT06261957?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06261957's enrollment target sits among peer trials
477 807th of 2000 higher than 1,193 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI